Meeting
2022 ASCO Quality Care Symposium
Factors predicting pathological complete response in patients with localized breast cancer receiving neoadjuvant chemotherapy.
Authors
Arya Mariam Roy
Roswell Park Comprehensive Cancer Center, Buffalo, NY
Arya Mariam Roy, Kristopher Attwood, Shipra Gandhi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Cost, Value, and Policy,Health Care Access, Equity, and Disparities,Patient Experience
Sub Track
Cancer Outcome Disparities
Citation
J Clin Oncol 40, 2022 (suppl 28; abstr 165)
DOI
10.1200/JCO.2022.40.28_suppl.165
Abstract #
165
Poster Bd #
E34
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Metformin with neoadjuvant chemotherapy in localized triple negative and HER2neu-positive breast cancer: A prospective phase 2 open label randomised controlled trial (McBETH).
First Author: Mouna Bidaraguppe B M
Poster
2023 ASCO Annual Meeting
Longitudinal MRI-based fusion novel model to predict pathological complete response in breast cancer treated with neoadjuvant chemotherapy: A multicenter, retrospective study.
First Author: Kun Wang
Poster
2023 ASCO Annual Meeting
Selective avoidance of sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with HER-2 positive/triple negative breast cancer: Prospective, multi-center, single-arm study (ASLAN).
First Author: Jai Min Ryu
Poster
2022 ASCO Annual Meeting
Does race influence long-term outcomes after neoadjuvant chemotherapy in breast cancer: A National Cancer Database analysis.
First Author: Arya Mariam Roy